HONG KONG,Dec. 24,2024-- In partnership with JCDecaux Transport,Airport Authority (AAHK)and The Shilla Duty Free,Dior adds a sprinkle of glitter to Hong Kong International Airport (HKIA) for this fest
Higher resolution and wider field of view,enabling driver and passenger monitoring with a single camera
LG'S LATEST INDOOR GARDENING APPLIANCE SHOWS OFF FRESH NEW DESIGN AT CES 2025
Featuring Sophisticated Lighting and Enhanced Usability,Company\'s Home Gardening Lifestyle Solution Brings the Beauty and Bounty of Nature Indoors
LOS ANGELES,Dec. 24,2024-- Leading global live streaming platformBuzzCast has officially launched Phase One of its Web App,bringing users a faster,more efficient way to connect and enjoy live streamin
Heaven and Earth Create Yin and Yang: The Cosmic World on the Tip of the Tongue
BEIJING,Dec. 24,2024--In 2024,the third season ofViews on Civilizationreturns,featuring Latvian scholar Anzelika Smirnova and distinguished Chinese guests engaging in rich storytelling and in-depth in
Debut Hong Kong Fashion Fest wraps up in style
Reinforcing Hong Kong\'s vital role in the global fashion scene HONG KONG,Dec. 20,2024-- The inaugural "Hong Kong Fashion Fest" concluded on 4 December 2024 with resounding success,attracti
GDIN Celebrates Key Achievements in 2024 Overseas Expansion Program
122 Companies Supported; USD 246.6 Million in Investments Secured SEOUL,South Korea,Dec. 20,2024--Global Digital Innovation Network (GDIN),under the leadership of CEO Jongkap Kim,proudly announces the
BEIJING,Dec. 20,2024-- Xiwangzhuang Town in Shizhong District of Zaozhuang City,east China\'s Shandong Province,has made efforts to advance rural revitalization through the development of the distinct
Pullman Danang Beach Resort Unveils Newly Renovated Grand Ballroom
DANANG,Vietnam,Dec. 20,2024-- Pullman Danang Beach Resort is thrilled to announce the grand unveiling of its newly renovated grand ballroom and MICE (Meetings,Incentives,Conferences,and Exhibitions) f
SHANGHAI,Dec. 21,2024-- YolTech Therapeutics today announced updated data from its ongoing Phase I/IIa clinical trial of YOLT-201,a first-in-class CRISPR/Cas9-based in vivo gene-editing therapy for AT